Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

In various embodiments, the present disclosure pertains to compositions for medical use. In some embodiments, the compositions comprise an aqueous solution of a block copolymer that comprises one or more poly(N-isopropylamino acrylamide) blocks and one or more poly(2-(di-(C.sub.1-5)alkylamino) (C.sub.1-5)alkyl methacrylate) blocks. In some embodiments, the compositions are in liquid form at 25° C. Other embodiments pertain to methods that comprise delivering such compositions to a patient.

Hydrogel compositions prepared from amine components and glycidyl ether components are provided which are biocompatible and suitable for use in vivo due, in part, to their excellent stability.

A vaso-occlusive device is constructed out of dissimilar metallic materials that are in contact or otherwise in close proximity with one another, thereby causing the device to undergo galvanic corrosion when exposed to an electrolytic medium, such as blood or other body fluid, wherein one of the dissimilar metallic materials is zirconium or zirconium alloy to create a corrosive product including zirconia having a relatively high hardness, a relatively high fracture toughness, and a relatively high stability when the device is implanted in a vasculature site, such as an aneurysm.

The present disclosure describes drug-loaded nanoparticles for hepatic artery chemoembolization, wherein the drug-loaded nanoparticles are novel doxorubicin-loaded metal organic framework (MOF) nanoparticles and UiO-66/Bi.sub.2S.sub.3 nanocomposites. The preparation method of the drug-loaded nanoparticles includes the following steps: mixing UiO-66/Bi.sub.2S.sub.3 with DOX solution, stirring the resultant mixture overnight at 25° C.±5° C. in a dark environment, centrifuging the mixture, and washing with deionized water to obtain UiO-66/UiO-66/Bi.sub.2S.sub.3@DOX composite nanomaterials. The present disclosure adopts a “one-pot reaction” with a simple preparation process. The pH-reactive release performance of the MOF material indicates that the tumor tissue of hepatocellular carcinoma (HCC) has a lower pH than normal tissue, and the acidic tumor environment can induce the release of doxorubicin from the nanomaterials. The MOF material has strong photothermal conversion ability, allowing HCC to be treated by photothermal treatment in combination with TACE.

Described herein are polymeric particles configured for intravascular delivery of pharmaceutical agents, e.g., to a diseased site, and methods of forming and using same. Preparation of these polymer particles is also described.

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.

Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

An hydrogel comprising chitosan and two weak bases having different pKb values. In some embodiments, one of the weak bases if sodium hydrogen carbonate (SHC). Also, use of the hydrogel in medical and cosmetic treatments.

Described are polymers and methods of forming and using same.